Website intended for a NZ health professional readership
We are on our summer break and the editorial office is closed until 13 January. In the meantime, please enjoy our Summer Hiatus series, in which our journalists curate an eclectic mix from our news and clinical archives throughout the year, The Conversation and other publications we share content with. Please note the comment function has been turned off while we are away. Happy reading!
This article was first published online on 5 June.
Sexual health specialist Massimo Giola looks at the evidence for doxycycline post-exposure prophylaxis as a prevention tool for syphilis, chlamydia and gonorrhoea
1. Highleyman L. Sexually transmitted infections in San Francisco have fallen since doxyPEP roll-out. 5 March 2024.
2. Centers for Disease Control and Prevention. Guidelines for the use of doxycycline post-exposure prophylaxis for bacterial sexually transmitted infection prevention. October 2023.
3. Cornelisse VJ, Ong JJ, Ryder N, et al. Interim position statement on doxycycline post-exposure prophylaxis (Doxy-PEP) for the prevention of bacterial sexually transmissible infections in Australia and Aotearoa New Zealand - the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM). Sex Health 2023;20(2):99–104.
Pharmacist prescribers Linda Bryant and Leanne Te Karu discuss positive polypharmacy for heart failure. Current evidence shows the intensive implementation of four medications offers the greatest benefit to most patients with heart failure, with significant reductions in cardiovascular mortality, heart failure hospitalisations and all-cause mortality
